Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

David Isenberg,Richard Furie,Nicholas S. Jones,Pascal Guibord,Joshua Galanter,Chin Lee,Anna McGregor,Balazs Toth,Julie Rae,Olivia Hwang,Rupal Desai,Armend Lokku,Nandhini Ramamoorthi,Jason A. Hackney,Pedro Miranda,Viviane A. Souza,Juan J. Jaller‐Raad,Anna Maura Fernandes,Rodrigo Garcia Salinas,Leslie W. Chinn,Michael J. Townsend,Alyssa M. Morimoto,Katie Tuckwell

DOI: https://doi.org/10.1002/art.41811

2021-08-24

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Fenebrutinib (GDC-0853, FEN) is a non-covalent, oral, and highly selective inhibitor of Bruton's tyrosine kinase (BTK). The efficacy, safety, and pharmacodynamics of FEN were assessed in this randomized, placebo-controlled, multi-center phase II study.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Patients with moderate-to-severely active systemic lupus erythematosus on background standard of care therapy were randomized to placebo, FEN 150 mg QD, or FEN 200 mg BID arms. Corticosteroid taper was recommended from weeks 0 to 12 (W0-W12) and W24-W36. The primary endpoint was SRI-4 at W48.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Patients (<i>N</i>=260) were enrolled from 44 sites in 12 countries, with the majority from Latin America, USA, and Western Europe. The SRI-4 response rates at W48 were 51% (<i>p</i>=0.37, versus placebo) for FEN 150 mg QD, 52% (<i>p</i>=0.34, versus placebo) for FEN 200 mg BID, and 44% for placebo. BICLA response rates at W48 were 53% (<i>p</i>=0.086, versus placebo) for FEN 150 mg QD, 42% (<i>p</i>=0.879, versus placebo) for FEN 200 mg BID, and 41% for placebo. Safety results were similar across all arms, although serious adverse events were more frequent with FEN 200 mg BID. By W48, patients treated with FEN had reduced levels of a BTK-dependent plasmablast RNA signature, anti-dsDNA autoantibodies, total IgG, and IgM, as well as increased complement C4, all relative to placebo. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>While FEN had an acceptable safety profile, the primary endpoint, SRI-4, was not met despite evidence of strong pathway inhibition.</p></section>

rheumatology